SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Two messenger RNA (mRNA)-based vaccines, BNT162b2 and mRNA-1273, are currently available for SARS-CoV-2. Both vaccines have been shown to induce protective immunity against SARS-CoV-2 for most healthy individuals.1 Recent studies have demonstrated a substantially lower rate of antibody induction by both SARS-CoV-2 mRNA vaccines among patients with immunosuppression, including individuals with cancer.2-5 However, the immunogenicity of SARS-CoV-2 mRNA vaccines among patients with selective B-cell deficiency is not well known.
Studies are ongoing to assess vaccine-induced antibody and T-cell responses among patients treated with chimeric antigen receptor (CAR) T cells that lead to substantial B-cell depletion in humans. Chimeric antigen receptor T-cell therapies targeting B-cell lineage antigens, most notably CD19 and CD22, have demonstrated remarkable success in inducing the remission of advanced B-cell–derived cancers and have been administered to more than 10 000 patients globally. A successful response to these therapies is often accompanied by substantial B-cell depletion lasting for months to years.6 We previously showed that despite persistent B-cell depletion, some patients maintain preexisting protective humoral immunity.6 However, to our knowledge, their ability to mount new antibody responses and T-cell immunity has not yet been reported. Here, we determined whether patients with hematologic cancers treated with CAR T cells targeting the CD19 and/or CD22 B-cell lineage antigens can mount antibody and T-cell responses to SARS-CoV-2 vaccines.
JAMA Oncology , résumé, 2020